Taro Pharmaceutical Industries (NYSE:TARO – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued on Tuesday. Separately, TheStreet raised shares of Taro Pharmaceutical Industries from a “d+” rating to a “c-” rating in a report on Monday, June 26th. Read […]